C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 330—Over-The-Counter (Otc) Human Drugs Which Are Generally Recognized As Safe and Effective and Not MisbrandedSubpart A—General Provisions

21 C.F.R. § 330.1 (2026)

General conditions for general recognition as safe, effective and not misbranded

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 ACTIVE · 19 IN 5Y cited 1969–2026 30citing cases
At a glance

Courts have cited this section in 30 opinions since 1969, 19 of them in the last five years. The most litigated part is subsection (c)(1) (1 case).

An over-the-counter (OTC) drug listed in this subchapter is generally recognized as safe and effective and is not misbranded if it meets each of the conditions contained in this part and each of the conditions contained in any applicable monograph. Any product which fails to conform to each of the conditions contained in this part and in an applicable monograph is liable to regulatory action.

(a) The product is manufactured in compliance with current good manufacturing practices, as established by parts 210 and 211 of this chapter.

(b) The establishment(s) in which the drug product is manufactured is registered, and the drug product is listed, in compliance with part 207 of this chapter. It is requested but not required that the number assigned to the product pursuant to part 207 of this chapter appear on all drug labels and in all drug labeling. If this number is used, it shall be placed in the manner set forth in part 207 of this chapter.

(c)(1) The product is labeled in compliance with chapter V of the Federal Food, Drug, and Cosmetic Act (the act) and subchapter C et seq. of this chapter, including the format and content requirements in § 201.66 of this chapter. An OTC drug product that is not in compliance with chapter V and subchapter C, including § 201.66 of this chapter, is subject to regulatory action. For purposes of § 201.61(b) of this chapter, the statement of identity of the product shall be the term or phrase used in the applicable OTC drug monograph established in this part.

(2) The “Uses” section of the label and labeling of the product shall contain the labeling describing the “Indications” that have been established in an applicable OTC drug monograph or alternative truthful and nonmisleading statements describing only those indications for use that have been established in an applicable monograph, subject to the provisions of section 502 of the act relating to misbranding and the prohibition in section 301(d) of the act against the introduction or delivery for introduction into interstate commerce of unapproved new drugs in violation of section 505(a) of the act. Any other labeling under this subchapter and subchapter C et seq. of this chapter shall be stated in the exact language where exact language has been established and identified by quotation marks in an applicable OTC drug monograph or by regulation (e.g., § 201.63 of this chapter), except as provided in paragraphs (i) and (j) of this section.

(d) The advertising for the product prescribes, recommends, or suggests its use only under the conditions stated in the labeling.

(e) The product contains only suitable inactive ingredients which are safe in the amounts administered and do not interfere with the effectiveness of the preparation or with suitable tests or assays to determine if the product meets its professed standards of identity, strength, quality, and purity. Color additives may be used only in accordance with section 721 of the act and subchapter A of this chapter.

(f) The product container and container components meet the requirements of § 211.94 of this chapter.

(g) The labeling for all drugs contains the general warning: “Keep out of reach of children.” [highlighted in bold type]. The labeling of drugs shall also state as follows: For drugs used by oral administration, “In case of overdose, get medical help or contact a Poison Control Center right away”; for drugs used topically, rectally, or vaginally and not intended for oral ingestion, “If swallowed, get medical help or contact a Poison Control Center right away”; and for drugs used topically and intended for oral use, “If more than used for” (insert intended use, e.g., pain) “is accidentally swallowed, get medical help or contact a Poison Control Center right away.” The Food and Drug Administration will grant an exemption from these general warnings where appropriate upon petition, which shall be maintained in a permanent file for public review by the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

(h) Where no maximum daily dosage limit for an active ingredient is established in this part, it is used in a product at a level that does not exceed the amount reasonably required to achieve its intended effect.

(i) The following terms may be used interchangeably in the labeling of OTC drug products, provided such use does not alter the meaning of the labeling that has been established and identified in an applicable monograph or by regulation. The following terms shall not be used to change in any way the title, headings, and subheadings required under § 201.66(c)(1) through (c)(9) of this chapter:

(1) “Abdominal” or “stomach” (in context only).

(2) “Administer” or “give”.

(3) “Aggravate(s)” or “make(s) worse”.

(4) “Application of this product” or “applying”.

(5) “Are uncertain” or “do not know”.

(6) “Ask” or “consult” or “contact”.

(7) “Asking” or “consulting”.

(8) “Assistance” or “help” or “aid”.

(9) “Associated with” or “due to” or “caused by”.

(10) “Avoid contact with eyes” or “do not get into eyes”.

(11) “Avoid inhaling” or “do not inhale”.

(12) “Before a doctor is consulted” or “without first consulting your doctor” or “consult your doctor before”.

(13) “Beverages” or “drinks”.

(14) “Clean” or “cleanse”.

(15) “Consulting” or “advising”.

(16) “Continue(s)” or “persist(s)” or “is persistent” or “do(es) not go away” or “last(s)”.

(17) “Daily” or “every day”.

(18) “Develop(s)” or “begin(s)” or “occur(s)”.

(19) “Difficulty” or “trouble”.

(20) “Difficulty in urination” or “trouble urinating”.

(21) “Discard” or “throw away”.

(22) “Discontinue” or “stop” or “quit”.

(23) “Doctor” or “physician”.

(24) “Drowsiness” or “the drowsiness effect”.

(25) “Drowsiness may occur” or “you may get drowsy”.

(26) “Enlargement of the” or “an enlarged”.

(27) “Especially in children” or especially children”.

(28) “Exceed” or “use more than” or “go beyond”.

(29) “Exceed recommended dosage” or “use more than directed”.

(30) “Excessive” or “too much”.

(31) “Excitability may occur” or “you may get excited”.

(32) “Experience” or “feel”.

(33) “For relief of” or “relieves”.

(34) “For temporary reduction of” or “temporarily reduces”.

(35) “For the temporary relief of” or “temporarily relieves”.

(36) “For the treatment of” or “treats”.

(37) “Frequently” or “often”.

(38) “Give to” or “use in”.

(39) “Immediately” or “right away” or “directly”.

(40) “Immediately” or “as soon as”.

(41) “Immediately following” or “right after”.

(42) “Improve(s)” or “get(s) better” or “make(s) better”.

(43) “Increased” or “more”.

(44) “Increase your risk of” or “cause”.

(45) “Indication(s)” or “Use(s)”.

(46) “Inhalation” or “puff”.

(47) “In persons who” or “if you” or “if the child”.

(48) “Instill” or “put”.

(49) “Is (are) accompanied by” or “you also have” (in context only) or “(optional: that) occur(s) with”.

(50) “Longer” or “more”.

(51) “Lung” or “pulmonary”.

(52) “Medication(s)” or “medicine(s)” or “drug(s)”.

(53) “Nervousness, dizziness, or sleeplessness occurs” or “you get nervous, dizzy, or sleepless”.

(54) “Not to exceed” or “do not exceed” or “not more than”.

(55) “Obtain(s)” or “get(s)”.

(56) “Passages” or “passageways” or “tubes”.

(57) “Perforation of” or “hole in”.

(58) “Persistent” or “that does not go away” or “that continues” or “that lasts”.

(59) “Per day” or “daily”.

(60) “Presently” or “now”.

(61) “Produce(s)” or “cause(s)”.

(62) “Prompt(ly)” or “quick(ly)” or “right away”.

(63) “Reduce” or “minimize”.

(64) “Referred to as” or “of”.

(65) “Sensation” or “feeling”.

(66) “Solution” or “liquid”.

(67) “Specifically” or “definitely”.

(68) “Take” or “use” or “give”.

(69) “Tend(s) to recur” or “reoccur(s)” or “return(s)” or “come(s) back”.

(70) “To avoid contamination” or “avoid contamination” or “do not contaminate”.

(71) “To help” or “helps”.

(72) “Unless directed by a doctor” or “except under the advice of a doctor” or “unless told to do so by a doctor”.

(73) “Use caution” or “be careful”.

(74) “Usually” or “generally” (in context only).

(75) “You” (“Your”) or “the child” (“the child's”).

(76) “You also have” or “occurs with”.

(77) “When practical” or “if possible”.

(78) “Whether” or “if”.

(79) “Worsen(s)” or “get(s) worse” or “make(s) worse”.

(j) The following connecting terms may be deleted from the labeling of OTC drug products, provided such deletion does not alter the meaning of the labeling that has been established and identified in an applicable monograph or by regulation. The following terms shall not be used to change in any way the specific title, headings, and subheadings required under § 201.66(c)(1) through (c)(9) of this chapter:

(1) “And”.

(2) “As may occur with”.

(3) “Associated” or “to be associated”.

(4) “Consult a doctor”.

(5) “Discontinue use”.

(6) “Drug Interaction Precaution”.

(7) “Due to”.

(8) “Except under the advice and supervision of a physician”.

(9) “If this occurs”.

(10) “In case of”.

(11) “Notice”.

(12) “Or”.

(13) “Occurring with”.

(14) “Or as directed by a doctor”.

(15) “Such as”.

(16) “Such as occurs with”.

(17) “Tends to”.

(18) “This product”.

(19) “Unless directed by a doctor”.

(20) “While taking this product” or “before taking this product”.

(21) “Within”.

[39 FR 11741, Mar. 29, 1974, as amended at 40 FR 11718, Mar. 13, 1975; 40 FR 13496, Mar. 27, 1975; 42 FR 15674, Mar. 22, 1977; 46 FR 8459, Jan. 27, 1981; 50 FR 8996, Mar. 6, 1985; 51 FR 16266, May 1, 1986; 55 FR 11581, Mar. 29, 1990; 59 FR 4000, Jan. 28, 1994; 59 FR 14365, Mar. 28, 1994; 64 FR 13294, Mar. 17, 1999; 68 FR 24879, May 9, 2003; 88 FR 45066, July 14, 2023]
The 20 cases that cite 21 C.F.R. § 330.1 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENKanter v. Warner-Lambert Co., 99 Cal. App. 4th 780 (Ct. App. 2002).
cites § 330.1 4×cited by 36 cases
Where it cites § 330.1
“Under the over-the-counter drug monograph system, the FDA appoints advisory review panels of qualified experts to evaluate the safety and effectiveness of over-the-counter drugs, to review their labeling, and to advise on the promulgation of monographs establishing conditions…”
The case’s holding
A state law claim is preempted if it effectively requires a manufacturer to include additional or different information on a federally approved label.
Later courts cite it for
“when a state law claim . . . would effectively require a manufacturer to include additional or different information on a federally approved label, it is preempted” · 5 citing courts
2
GREENMills v. Warner-Lambert Co., 581 F. Supp. 2d 772 (E.D. Tex. 2008).
cites § 330.1 4×cited by 17 cases
Where it cites § 330.1
““Any product which fails to conform” to “each of the conditions contained in the monograph and 21 C.F.R. 330.1 is “liable to regulatory action.”
Later courts cite it for
“only reasonable inferences in favor of the nonmoving party can be drawn from the evidence.” · 7 citing courts
3
GREENMcNeilab, Inc. v. Am. Home Prods. Corp., 501 F. Supp. 517 (S.D.N.Y. 1980).
cites § 330.1 1×cited by 58 cases
Where it cites § 330.1
“See 21 C.F.R. §§ 330.1 -.13. In the Review, the 300 to 500 significant active ingredients *534 found in the 300,000 to 500,000 OTC drug products on the market were classified into therapeutic categories, such as ant-acids, laxatives, cold remedies, and internal analgesics.”
The case’s holding
A failure to inform consumers of certain facts does not constitute a per se actionable misrepresentation under section 43(a) of the Lanham Act.
Later courts cite it for
“a failure to inform consumers of something, even something that they should know, is not per se a 731 misrepresentation actionable under section 43(a) of the lanham act.” · 3 citing courts
4
GREENCarter v. Novartis Consum. Health, Inc., 582 F. Supp. 2d 1271 (C.D. Cal. 2008).
cites § 330.1 1×cited by 13 cases
Later courts cite it for
“expands the universe of potentially preempted state law claims to include that those require additional warnings in the advertising for nonprescription drugs, and not only on the labeling.” · 2 citing courts
5
GREENAm. Home Prods. Corp. v. Johnson & Johnson, 436 F. Supp. 785 (S.D.N.Y. 1977).
cites § 330.1 1×cited by 29 cases
Where it cites § 330.1
“21 CFR 330.1, 330.5 and 330.10. Thus we do not think that it is within the province of this court to go beyond the issue of the falsity of the advertisement’s representations and consider whether the public interest is well served by allowing such representations to be made.”
The case’s holding
The critical factor in determining whether an advertisement makes false representations under the Lanham Act is the message the consumer takes from the language used.
Later courts cite it for
“not confident that the gr technique really tested what message the consumer took from the language used as opposed to the broader issue of what mental processes viewers went through when they noticed an anacin ad appear on the screen.” · 2 citing courts
6
GREENBristol-Myers Co. v. Fed. Trade Comm'n, 738 F.2d 554 (2d Cir. 1984).
cites § 330.1 1×cited by 26 cases
Summary
No passage or summary on file for this case yet.
7
GREENDelarosa v. Boiron, Inc., 818 F. Supp. 2d 1177 (C.D. Cal. 2011).
cites § 330.1 1×cited by 8 cases
Where it cites § 330.1
“See 21 C.F.R. §§ 330.1 , 330.10. In drafting the monographs, the FDA divided the non-homeopathic OTC drugs into drug categories, such as antacids, laxatives, antidiarrheal products, emetics, antiemetics, antiperspirants, etc.”
8
GREENJaekel v. United States, 304 F. Supp. 993 (S.D.N.Y. 1969).
cites § 330.1 1×cited by 50 cases
Where it cites § 330.1
“(now 21 C.F.R. § 330.1 , et seq.), are inconsistent with the statute, 19 U.”
The case’s holding
The government is liable for the value of an automobile's depreciation from the date of seizure when notice by publication alone is constitutionally inadequate.
9
GREENIn re Colgate-Palmolive MDL, 2013 DNH 038 (D.N.H. 2013).
cites § 330.1 2×cited by 1 case
Where it cites § 330.1
“21 C.F.R. § 330.1 . Drugs must conform to monograph conditions, and no aspect of the product’s label may be false or misleading.”
10
GREENBober, Estelle v. Glaxo Wellcome PLC, 246 F.3d 934 (7th Cir. 2001).
cites § 330.1 3×cited by 2 cases
Where it cites § 330.1
“(52) “medication(s)” or “medicine(s)” or “drug(s)” 21 C.F.R. § 330.1 (i). This provision indicates that, with respect to labeling Zantac 75, Glaxo was specifically authorized to use the terms “drugs” and “medications” as synonyms.”
The case’s holding
A statement is deceptive under the Illinois Consumer Fraud Act if it creates a likelihood of deception or has the capacity to deceive.
Later courts cite it for
“a statement is deceptive if it creates a likelihood of deception or has the capacity to deceive.” · 46 citing courts
11
NO FLAGHatfield v. Wal-Mart Stores, Inc., No. 1:22-cv-09011 (S.D.N.Y. Nov. 14, 2022).
cites § 330.1 5×cited by 0 casesunknown
Where it cites § 330.1
“4 See 21 C.F.R. § 330.1 . Critically, if the drug meets the required conditions and is therefore GRAS/E, it is not a “new drug” that requires premarket approval.”
12
NO FLAGLester v. CVS Pharmacy, Inc., No. 1:22-cv-07334 (S.D.N.Y. Mar. 27, 2024).
cites § 330.1 5×subsections: (c)(2)cited by 0 casesunknown
Where it cites § 330.1
“” 21 C.F.R. § 330.1 . These conditions include the format and content of product labeling.”
13
NO FLAGNavarro v. Walgreens Boots All., Inc., No. 1:24-cv-00290, 2025 WL 1411406 (E.D. Cal. May 15, 2025).
cites § 330.1 5×cited by 0 casesunknown
Where it cites § 330.1
“]” 21 C.F.R. § 330.1 . The “conditions 13 contained in this part” include a requirement that “(a) [t]he product is manufactured in 14 compliance with current good manufacturing practices, as established by parts 210 and 211 of 15 this chapter.”
14
NO FLAGJordan Eisman v. Johnson & Johnson Consum. Companies, Inc., No. 2:24-cv-01982 (C.D. Cal. Jan. 17, 2025).
cites § 330.1 4×cited by 0 casesunknown
Where it cites § 330.1
“21 C.F.R. §§ 330.1 , 26 358.701. The FDA promulgated its monograph for OTC Coal Tar drug products after 27 an extensive review process involving the recommendations of an expert advisory 28 panel and public notice and comment.”
15
NO FLAGIn re Target Corp. BPO Sales & Mktg. Litig., No. 0:24-cv-01323 (D. Minn. Jan. 20, 2026).
cites § 330.1 4×subsections: (c)(1)cited by 0 casesunknown
Where it cites § 330.1
““Any product which fails to conform to each of the conditions” contained in 21 C.F.R. § 330.1 “and in an applicable monograph is liable to regulatory action.”
16
NO FLAGKouyate, No. 1:25-cv-01013 (W.D. Mich. Mar. 3, 2026).
cites § 330.1 4×cited by 0 casesunknown
Where it cites § 330.1
“Such a drug “is generally recognized as safe and effective and is not misbranded if it meets each of the conditions contained in [ 21 C.F.R. § 330.1 ] and each of the conditions contained in any applicable monograph.”
cites § 330.1 2×cited by 1 case
Where it cites § 330.1
“l5 CHAPTER 32b — DRUGS—MISBRANDING SUBJECT: OTC Drugs — General Provisions and Administrative Procedures •for Recognition as Safe and Effective BACKGROUND AND POLICY: An OTC drug listed in subchapter 21 CFR 330 is generally recognized as safe and effective and is not misbranded…”
18
NO FLAGHall v. Walgreens Boots All., Inc., 565 P.3d 564 (Wash. 2025).
cites § 330.1 3×cited by 0 cases
Where it cites § 330.1
“Over-the-counter medicines are subject to regulation by the United States Food and Drug Administration (FDA). See 21 U.S.C. ch. 9 (Federal Food, Drug, and Cosmetic Act).”
19
NO FLAGHall v. Walgreens Boots All., Inc., 565 P.3d 564 (Wash. 2025).
cites § 330.1 3×cited by 0 cases
Where it cites § 330.1
“Over-the-counter medicines are subject to regulation by the United States Food and Drug Administration (FDA). See 21 U.S.C. ch. 9 (Federal Food, Drug, and Cosmetic Act).”
20
NO FLAGPineda v. Lake Consum. Prods., Inc., No. 5:24-cv-01074 (E.D. Pa. Sept. 22, 2025).
cites § 330.1 3×cited by 0 casesunknown
Where it cites § 330.1
“21 C.F.R. §§ 330.1 , 358.701. The FDA issued the monograph for coal tar as to certain scalp conditions in 1991, and it specified, in relevant part, the permissible active ingredients and their concentrations, indications for use, warnings, directions and other mandatory labeling…”

Show all 30 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
196919972026

One bar per year. Tallest: 6 cases in 2025. 2026 is a partial year. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
N.D. Ill.6S.D.N.Y.6C.D. Cal.3Wash.22d Cir.17th Cir.1E.D. Cal.1Cal. Ct. App.1

The 8 courts with the most citing cases, of 17 courts in all.

By subsection
(c)(1)1 case
In re Target Corp. BPO Sales & Mktg. Litig., No. 0:24-cv-01323 (D. Minn. Jan. 20, 2026).““Any product which fails to conform to each of the conditions” contained in 21 C.F.R. § 330.1 “and in an applicable monograph is liable to regulatory action.”
(c)(2)1 case
Lester v. CVS Pharmacy, Inc., No. 1:22-cv-07334 (S.D.N.Y. Mar. 27, 2024).“” 21 C.F.R. § 330.1 . These conditions include the format and content of product labeling.”

Show all 30 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com